학술논문

AARS2‐related ovarioleukodystrophy: Clinical and neuroimaging features of three new cases.
Document Type
Article
Source
Acta Neurologica Scandinavica. Oct2018, Vol. 138 Issue 4, p278-283. 6p.
Subject
*LEUKODYSTROPHY
*OVARIAN diseases
*PREMATURE ovarian failure
*BRAIN imaging
*PROGRESSIVE multifocal leukoencephalopathy
Language
ISSN
0001-6314
Abstract
Introduction: Adult‐onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), previously known as hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS) or pigmentary orthochromatic leukodystrophy (POLD), is the most frequent non‐vascular adult‐onset leukoencephalopathy. It is caused by autosomal dominant mutations in CSF1R gene. Recently, also autosomal recessive mutations in AARS2 gene were found to be the cause of an adult‐onset leukodystrophy with axonal spheroids. Our aim was to achieve a genetic diagnosis in a cohort of CSF1R‐negative patients, performing a sequence analysis of AARS2 gene. Material and Methods: AARS2 sequencing was performed in 38 CSF1R‐negative patients with clinical and magnetic resonance imaging (MRI) findings of adult‐onset leukoencephalopathy. Results: Three patients carrying AARS2 compound heterozygous mutations have been found. All patients were female with ovarian failure and leukoencephalopathy. In 2 patients, MRI findings were consistent with previous reports while the third patient showed focal white matter (WM) lesions in the centrum semiovale and the corpus callosum in the absence of extensive involvement and rarefaction of the WM. MRI spectroscopy showed the presence of increased lactate in 2 patients, thus linking AARS2‐related leukoencephalopathy with other mitochondrial leukoencephalopathies with high levels of cerebral lactate. Conclusion: We recommend screening for mutations in AARS2 gene in CSF1R‐negative patients, also in the absence of a clear family history and peculiar MRI findings. Our results also suggest that findings of conventional MRI and MR spectroscopy may be useful in prompting the genetic screening. [ABSTRACT FROM AUTHOR]